New trial for Lung NETs (lung neuroendocrine tumors)

Portal Forums Cancer Basics Clinical Trials and Drug Development New trial for Lung NETs (lung neuroendocrine tumors)

Tagged: ,

This topic contains 2 replies, has 2 voices, and was last updated by JimC Forum Moderator JimC Forum Moderator 4 weeks, 1 day ago.

Viewing 3 posts - 1 through 3 (of 3 total)
Author Posts   
Author Posts
September 21, 2017 at 12:29 am  #1293144    

trialbee

Would you be interested to participate in a clinical trial evaluating the efficacy and safety of an investigative drug for Lung Neuroendocrine Tumors (Lung NETs)?

This clinical study is being conducted to evaluate an investigative treatment for Lung Neuroendocrine Tumors (Lung NETs). You may have heard of this condition being called Lung Carcinoid Tumors, Bronchial NETs, or Pulmonary NETs.

A total of 216 patients will be a part of this global study, which has been approved by the FDA and relevant ethics committees. We are looking for both males and females, aged 18 years or older, who are diagnosed with a neuroendocrine tumor of the lung (Lung NET).

Read more here.

September 21, 2017 at 8:36 am  #1293147    
JimC Forum Moderator
JimC Forum Moderator

GRACE makes no specific endorsement of any trial posted on this site, nor has GRACE evaluated its likelihood of success.

It appears that this trial is listed on clinicaltrials.gov here: https://clinicaltrials.gov/ct2/show/study/NCT02683941?term=neuroendocrine+AND+placebo&recrs=a&cond=LUNG+CANCER&rank=1&show_locs=Y#locn

Patients interested in this trial should be aware that two-thirds of the trial participants will receive the investigational drug, while one-third will receive a placebo and “best supportive care”, but no anti-cancer therapy until their disease progresses, at which time they will become eligible to receive the trial drug.

JimC
Forum moderator


Jul 2008 Wife Liz (51/never smoker) Dx Stage IV NSCLC EGFR exon 19
4 cycles Carbo/alimta, 65% shrinkage
Tarceva maintenance
Mar 2010 progression, added Alimta, stable
Sep 2010 multiple brain mets, WBR
Oct 2010 large pericardial effusion, tamponade
Jan 2011 progression, start abraxane
Jun 2011-New liver, brain mets, add Tarceva
Oct 2011-Dx Leptomeningeal carcinomatosis; pulsed Tarceva
At rest Nov 4 2011
Since then: http://cancergrace.org/blog/jim-and-lisa

September 21, 2017 at 8:44 am  #1293148    
JimC Forum Moderator
JimC Forum Moderator

Dr. Weiss has previously written about the trial drug Lanreotide (Somatuline Depot Injection) and had this to say (note that his post was 5 years ago, but we have nothing more recent than that):

“Apparently, somatuline is a somatostatin analogue. I realize that this may not mean much to many, but Dr. West and Dr. Pinder will recognize this as a class of drugs used to treat carcinoid tumors and severe diarrhea. I would not utilize this drug off trial to treat NSCLC other than perhaps pulmonary carcinoid. I would consider it in a clinic trial, especially if it were given with an agent known to be active or to patients with slow growing cancers. I don’t have experience with the agent, but if it’s like sandostatin (the somatostatin analogue that I do have experience with) I would expect side effects to be minimal.”http://cancergrace.org/topic/somatuline-lp-60#post-1246261

JimC
Forum moderator


Jul 2008 Wife Liz (51/never smoker) Dx Stage IV NSCLC EGFR exon 19
4 cycles Carbo/alimta, 65% shrinkage
Tarceva maintenance
Mar 2010 progression, added Alimta, stable
Sep 2010 multiple brain mets, WBR
Oct 2010 large pericardial effusion, tamponade
Jan 2011 progression, start abraxane
Jun 2011-New liver, brain mets, add Tarceva
Oct 2011-Dx Leptomeningeal carcinomatosis; pulsed Tarceva
At rest Nov 4 2011
Since then: http://cancergrace.org/blog/jim-and-lisa

Viewing 3 posts - 1 through 3 (of 3 total)

You must be logged in to reply to this topic.